☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
BeiGene
BeiGene to Highlight Data from P-III (SEQUOIA) Study of Brukinsa in Combination with Venetoclax for CLL/SLL at EHA2024
June 14, 2024
The US FDA Grants Approval to BeiGene’s Tevimbra to Treat Advanced or Metastatic Esophageal Squamous Cell Carcinoma
March 15, 2024
BeiGene’s Brukinsa Receives the US FDA’s Accelerated Approval for the Treatment of Follicular Lymphoma (FL)
March 8, 2024
BeiGene Reports Results from a Comparative Analysis of Brukinsa vs Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia...
March 1, 2024
BeiGene’s Tevimbra (tislelizumab) Receives CHMP’s Positive Opinion for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
February 27, 2024
Insights+: EMA Marketing Authorization of New Drugs in November 2023
December 29, 2023
Load more...
Back to Home